

Open peer review and authors' responses

Towards a treatment for mitochondrial disease: current compounds in clinical development

Authors: Åsander Frostner E, Simón Serrano S, Chamkha I, Donnelly E, Elmér E, Hansson MJ

Manuscript submitted 2022-04-14, 2022-05-16 (revision)

Manuscript accepted 2022-05-23

<https://doi.org/10.26124/bec:2022-0004>

Reviewer 2

Roberto Scatena

Laboratory Medicine Service, Vannini Hospital, Rome, IT

Manuscript reviewed 2022-05-05

<https://doi.org/10.26124/bec:2022-0004.r2>

*Only major points from review and responses included.

Reviewer 2

This manuscript deals with an interesting but tangled therapeutic topic. It is well written and organized. A negative aspect could be the concision of treatment that risks falling into superficiality. I would propose a more deepened bibliographic research and more careful description of pharmacokinetics and pharmacodynamics problems related to mitochondrial pharmacology.

Authors

We agree with the reviewer that additional aspects of mitochondrial pharmacology would be an interesting addition to the paper. Due to the page limit, however, this brief review focuses on small molecules in ongoing clinical trials for primary mitochondrial diseases conducted by industrial sponsors. In the paper, each compound is introduced in relation to general mechanism of action, targeted patients, and main clinical trials objectives and results. Unfortunately, more in depth information on each pharmacological strategy has not been possible to include. However, the revised version of the manuscript does include some further information and background for several compounds.